Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.32%
1,100.57
-3.53
-0.32%
—1,104.101,103.921,108.751,097.16——
SIXC
Communications
SIXC
Communications
SIXC
+0.16%
605.15
+0.99
+0.16%
—604.16604.16610.19604.12——
SIXE
Energy
SIXE
Energy
SIXE
-0.22%
1,195.19
-2.62
-0.22%
—1,197.811,200.581,213.071,192.02——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.03%
1,739.91
-0.50
-0.03%
—1,740.411,739.551,750.271,730.60——
SIXM
Financials
SIXM
Financials
SIXM
+0.65%
638.56
+4.12
+0.65%
—634.44633.13639.87633.01——
SIXR
Staples
SIXR
Staples
SIXR
-1.11%
831.57
-9.33
-1.11%
—840.90839.53841.73831.10——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.82%
213.36
-1.77
-0.82%
—215.13215.13215.85213.24——
SIXT
Technology
SIXT
Technology
SIXT
+0.17%
3,234.18
+5.47
+0.17%
—3,228.713,225.623,235.433,198.95——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.02%
935.65
-0.22
-0.02%
—935.87938.37942.00935.65——
SIXV
Health care
SIXV
Health care
SIXV
-0.54%
1,449.26
-7.86
-0.54%
—1,457.121,452.741,466.881,449.18——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,382.45
-17.39
-0.72%
—2,399.842,389.712,394.612,371.22——
GBIM:OTCMKTS
GlobeImmune Inc
$0.00010
0.00%
(0.00) 1D
Apr 16, 9:36:12 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GBIM...
Mkt. cap
580.00
Avg. vol.
173.00
Volume
0.00
52-wk high
$0.00
52-wk low
$0.00
Shares outstanding
5.75M
No. of employees
3
News stories
From sources across the web
Profile
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen. The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before. With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010. As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
About GlobeImmune Inc
CEO-
Employees3
FoundedJan 1, 1995
HeadquartersLouisville, Colorado, United States
SectorBiotechnology
Websiteglobeimmune.com
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
Revenue
Cost of goods sold
Cost of revenue
Research and development expenses
Total research and development expenses
Selling, general, and admin expenses
Operating expense
Total operating expenses
Operating income
Other non operating income
EBT including unusual items
EBT excluding unusual items
Income tax expense
Effective tax rate
Other operating expenses
Net income
Net profit margin
Earnings per share
Interest and investment income
Interest expense
Net interest expenses
Depreciation and amortization charges
EBITDA
Gain or loss from assets sale
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer